Loading...

Bryan King, MD, MBA

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentPsychiatry
Address401 Parnassus Ave.
San Francisco CA 94143
Phone415-502-1980
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, IrvineBS1979Biological Sciences
    Medical College of WisconsinMD 1983Medicine
    UCLA Center for Health SciencesInternship1984Internal Medicine
    UCLA Neuropsychiatric InstituteResidency in Psychiatry1987Psychiatry
    UCLA Neuropsychiatric InstituteFellowship in Child and Adolescent Psychiatry1990Psychiatry
    George Washington UniversityMBA2014Business
    Collapse Awards and Honors
    UC Irvine1979Phi Beta Kappa
    UC Irvine1979Magna Cum Laude
    UC Irvine1979Honors in Research
    NIMH1988Individual Research Service Award
    UCLA Neuropsychiatric Institute1988Gertrude Rogers Greenblatt Fellowship
    American Academy of Child and Adolescent Psychiatry1990George Tarjan Award
    UCLA Neuropsychiatric Institute Department of Nursing1997Outstanding Physician Award
    UCLA Neuropsychiatric Institute Department of Psychiatry1997Outstanding Mentor Award
    American Psychiatric Association2001Frank J. Menolascino Award
    Seattle Children's Hospital Family Advisory Council2007Annual Family Choice Award
    American Academy of Child and Adolescent Psychiatry2011Distinguished Fellow
    George Washington University School of Business2014Beta Gamma Sigma International Business Honor Society
    American Psychiatric Association2015Fellow

    Collapse Overview 
    Collapse Overview
    My research and clinical work has largely focused on psychiatric aspects of developmental disorders, and upon the pathogenesis and treatment of significant behavioral disturbance in autism and related disorders in particular. In recent years, this focus has been primarily directed on interventions in autism including both pharmacological and psychosocial treatments.


    Collapse Research 
    Collapse Research Activities and Funding
    2/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDD
    NIH/NIMH R01MH086927Jul 1, 2010 - Mar 31, 2014
    Role: Principal Investigator
    UW Autism Center of Excellence
    NIH/NICHD P50HD055782Aug 6, 2007 - Jul 31, 2013
    Role: Principal Investigator
    SELF INJURIOUS BEHAVIOR IN MENTAL RETARDATION
    NIH/NICHD R01HD033779Aug 1, 1996 - Jul 31, 2001
    Role: Principal Investigator
    SEROTONERGIC MECHANISMS AND SELF-INJURIOUS BEHAVIOR
    NIH/NIMH K20MH000917Feb 1, 1991 - Jan 31, 1997
    Role: Principal Investigator
    SEROTONIN RECEPTOR FUNCTION &CHILD PSYCHOPATHOLOGY
    NIH/NIMH F32MH009730Jan 25, 1989
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Politte LC, Scahill L, Figueroa J, McCracken JT, King B, McDougle CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018 Feb 27. PMID: 29540864.
      View in: PubMed
    2. Howes OD, Rogdaki M, Findon JL, Wichers RH, Charman T, King B, Loth E, McAlonan GM, McCracken JT, Parr JR, Povey C, Santosh P, Wallace S, Simonoff E, Murphy DG. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018 Jan; 32(1):3-29. PMID: 29237331.
      View in: PubMed
    3. King B. Association Between Maternal Use of SSRI Medications and Autism in Their Children. JAMA. 2017 04 18; 317(15):1568-1569. PMID: 28418468.
      View in: PubMed
    4. Veenstra-VanderWeele J, Cook EH, King B, Zarevics P, Cherubini M, Walton-Bowen K, Bear MF, Wang PP, Carpenter RL. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology. 2017 Jun; 42(7):1390-1398. PMID: 27748740.
      View in: PubMed
    5. Webb SJ, Garrison MM, Bernier R, McClintic AM, King B, Mourad PD. Severity of ASD symptoms and their correlation with the presence of copy number variations and exposure to first trimester ultrasound. Autism Res. 2017 Mar; 10(3):472-484. PMID: 27582229.
      View in: PubMed
    6. King B. Psychiatric comorbidities in neurodevelopmental disorders. Curr Opin Neurol. 2016 Apr; 29(2):113-7. PMID: 26840045.
      View in: PubMed
    7. King B. Assessing Risk of Autism Spectrum Disorder in Children After Antidepressant Use During Pregnancy. JAMA Pediatr. 2016 Feb; 170(2):111-2. PMID: 26660503.
      View in: PubMed
    8. Stein MA, King B. Unequal Individual Risk and Potential Benefit Balanced by Benefits to the Population at Large in Autism Clinical Trials? Am J Bioeth. 2016; 16(4):72-4. PMID: 26982936.
      View in: PubMed
    9. Kasari C, Dean M, Kretzmann M, Shih W, Orlich F, Whitney R, Landa R, Lord C, King B. Children with autism spectrum disorder and social skills groups at school: a randomized trial comparing intervention approach and peer composition. J Child Psychol Psychiatry. 2016 Feb; 57(2):171-9. PMID: 26391889.
      View in: PubMed
    10. Scahill L, McCracken JT, King B, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Am J Psychiatry. 2015 Dec; 172(12):1197-206. PMID: 26315981.
      View in: PubMed
    11. Carr T, Shih W, Lawton K, Lord C, King B, Kasari C. The relationship between treatment attendance, adherence, and outcome in a caregiver-mediated intervention for low-resourced families of young children with autism spectrum disorder. Autism. 2016 Aug; 20(6):643-52. PMID: 26290524.
      View in: PubMed
    12. Chowdhury M, Aman MG, Lecavalier L, Smith T, Johnson C, Swiezy N, McCracken JT, King B, McDougle CJ, Bearss K, Deng Y, Scahill L. Factor structure and psychometric properties of the revised Home Situations Questionnaire for autism spectrum disorder: The Home Situations Questionnaire-Autism Spectrum Disorder. Autism. 2016 Jul; 20(5):528-37. PMID: 26187059.
      View in: PubMed
    13. King B. Promising forecast for autism spectrum disorders. JAMA. 2015 Apr 21; 313(15):1518-9. PMID: 25898047.
      View in: PubMed
    14. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King B, Sahin M, Jansen A. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015 Jan; 52(1):25-35. PMID: 25532776; PMCID: PMC4427347.
      View in: PubMed, PubMed Central
    15. Dean M, Kasari C, Shih W, Frankel F, Whitney R, Landa R, Lord C, Orlich F, King B, Harwood R. The peer relationships of girls with ASD at school: comparison to boys and girls with and without ASD. J Child Psychol Psychiatry. 2014 Nov; 55(11):1218-25. PMID: 25039696; PMCID: PMC4269475.
      View in: PubMed, PubMed Central
    16. Kasari C, Lawton K, Shih W, Barker TV, Landa R, Lord C, Orlich F, King B, Wetherby A, Senturk D. Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT. Pediatrics. 2014 Jul; 134(1):e72-9. PMID: 24958585; PMCID: PMC4531276.
      View in: PubMed, PubMed Central
    17. King B. Sunsetting DSM-IV's pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 2014 May; 53(5):494-6. PMID: 24745948.
      View in: PubMed
    18. Lecavalier L, Wood JJ, Halladay AK, Jones NE, Aman MG, Cook EH, Handen BL, King B, Pearson DA, Hallett V, Sullivan KA, Grondhuis S, Bishop SL, Horrigan JP, Dawson G, Scahill L. Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder. J Autism Dev Disord. 2014 May; 44(5):1128-43. PMID: 24158679; PMCID: PMC3981870.
      View in: PubMed, PubMed Central
    19. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King B. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014 Apr; 44(4):958-64. PMID: 24272415.
      View in: PubMed
    20. King B, Navot N, Bernier R, Webb SJ. Update on diagnostic classification in autism. Curr Opin Psychiatry. 2014 Mar; 27(2):105-9. PMID: 24441420; PMCID: PMC4929984.
      View in: PubMed, PubMed Central
    21. Hilt RJ, Chaudhari M, Bell JF, Wolf C, Koprowicz K, King B. Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. J Child Adolesc Psychopharmacol. 2014 Mar; 24(2):83-9. PMID: 24506790; PMCID: PMC3967377.
      View in: PubMed, PubMed Central
    22. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014 Feb; 53(2):237-57. PMID: 24472258.
      View in: PubMed
    23. Hilt R, Wolf C, Koprowicz K, Thomas E, Chandler M, Hao XL, Russell M, Le T, Hooks L, King B. Community child psychiatric medication experiences measured by an internet-based, prospective parent survey of retail pharmacy customers. Community Ment Health J. 2014 Feb; 50(2):172-8. PMID: 24323138.
      View in: PubMed
    24. Scahill L, Aman MG, Lecavalier L, Halladay AK, Bishop SL, Bodfish JW, Grondhuis S, Jones N, Horrigan JP, Cook EH, Handen BL, King B, Pearson DA, McCracken JT, Sullivan KA, Dawson G. Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. Autism. 2015 Jan; 19(1):38-52. PMID: 24259748.
      View in: PubMed
    25. McClintic AM, King B, Webb SJ, Mourad PD. Mice exposed to diagnostic ultrasound in utero are less social and more active in social situations relative to controls. Autism Res. 2014 Jun; 7(3):295-304. PMID: 24249575; PMCID: PMC4025980.
      View in: PubMed, PubMed Central
    26. King B, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013 Nov; 167(11):1045-52. PMID: 24061784; PMCID: PMC4913472.
      View in: PubMed, PubMed Central
    27. Scahill L, Dimitropoulos A, McDougle CJ, Aman MG, Feurer ID, McCracken JT, Tierney E, Pu J, White S, Lecavalier L, Hallett V, Bearss K, King B, Arnold LE, Vitiello B. Children's Yale-Brown obsessive compulsive scale in autism spectrum disorder: component structure and correlates of symptom checklist. J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):97-107.e1. PMID: 24342389; PMCID: PMC3999641.
      View in: PubMed, PubMed Central
    28. Marrus N, Veenstra-Vanderweele J, Hellings JA, Stigler KA, Szymanski L, King B, Carlisle LL, Cook EH. Training of child and adolescent psychiatry fellows in autism and intellectual disability. Autism. 2014 May; 18(4):471-5. PMID: 24113341.
      View in: PubMed
    29. Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCracken JT, McDougle CJ, Tierney E, King B, Hollander E, Sikich L, Bregman J, Anagnostou E, Donnelly C, Katsovich L, Dukes K, Vitiello B, Gadow K, Scahill L. Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord. 2013 Oct; 43(10):2341-52. PMID: 23400347; PMCID: PMC4038127.
      View in: PubMed, PubMed Central
    30. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct; 49(4):255-65. PMID: 24053983; PMCID: PMC4058297.
      View in: PubMed, PubMed Central
    31. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct; 49(4):243-54. PMID: 24053982; PMCID: PMC4080684.
      View in: PubMed, PubMed Central
    32. Siegel M, King B. Autism and developmental disorders: management of serious behavioral disturbance. Child Adolesc Psychiatr Clin N Am. 2014 Jan; 23(1):xiii-xv. PMID: 24231174.
      View in: PubMed
    33. King B, de Lacy N, Siegel M. Psychiatric assessment of severe presentations in autism spectrum disorders and intellectual disability. Child Adolesc Psychiatr Clin N Am. 2014 Jan; 23(1):1-14. PMID: 24231163.
      View in: PubMed
    34. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013 Sep; 34(7):508-22. PMID: 24042082.
      View in: PubMed
    35. King B, Veenstra-Vanderweele J, Lord C. DSM-5 and autism: kicking the tires and making the grade. J Am Acad Child Adolesc Psychiatry. 2013 May; 52(5):454-7. PMID: 23622845.
      View in: PubMed
    36. Sterling L, Munson J, Estes A, Murias M, Webb SJ, King B, Dawson G. Fear-potentiated startle response is unrelated to social or emotional functioning in adolescents with autism spectrum disorders. Autism Res. 2013 Oct; 6(5):320-31. PMID: 23495221; PMCID: PMC4141562.
      View in: PubMed, PubMed Central
    37. de Lacy N, King B. Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology. Annu Rev Clin Psychol. 2013; 9:555-87. PMID: 23537488.
      View in: PubMed
    38. Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King B, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, Welsh JP. Consensus paper: pathological role of the cerebellum in autism. Cerebellum. 2012 Sep; 11(3):777-807. PMID: 22370873.
      View in: PubMed
    39. Swedo SE, Baird G, Cook EH, Happé FG, Harris JC, Kaufmann WE, King B, Lord CE, Piven J, Rogers SJ, Spence SJ, Wetherby A, Wright HH. Commentary from the DSM-5 Workgroup on Neurodevelopmental Disorders. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):347-9. PMID: 22449639.
      View in: PubMed
    40. Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, Bregman J, Sikich L, Dukes K, Sullivan L, Anagnostou E, Donnelly C, Kim YS, Ritz L, Hirtz D, Wagner A. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord. 2012 Mar; 42(3):432-40. PMID: 21667200.
      View in: PubMed
    41. Nord AS, Roeb W, Dickel DE, Walsh T, Kusenda M, O'Connor KL, Malhotra D, McCarthy SE, Stray SM, Taylor SM, Sebat J. Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. Eur J Hum Genet. 2011 Jun; 19(6):727-31. PMID: 21448237; PMCID: PMC3110052.
      View in: PubMed, PubMed Central
    42. King B, Lord C. Is schizophrenia on the autism spectrum? Brain Res. 2011 Mar 22; 1380:34-41. PMID: 21078305.
      View in: PubMed
    43. Yen CF, King B, Tang TC. The association between short and long nocturnal sleep durations and risky behaviours and the moderating factors in Taiwanese adolescents. Psychiatry Res. 2010 Aug 30; 179(1):69-74. PMID: 20472300.
      View in: PubMed
    44. Yen CF, King B, Chang YP. Factor structure of the Athens Insomnia Scale and its associations with demographic characteristics and depression in adolescents. J Sleep Res. 2010 Mar; 19(1 Pt 1):12-8. PMID: 19682243.
      View in: PubMed
    45. King B, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009 Jun; 66(6):583-90. PMID: 19487623; PMCID: PMC4112556.
      View in: PubMed, PubMed Central
    46. Brkanac Z, Raskind WH, King B. Pharmacology and genetics of autism: implications for diagnosis and treatment. Per Med. 2008 Nov; 5(6):599-607. PMID: 19727434.
      View in: PubMed
    47. Toth K, King B. Asperger's syndrome: diagnosis and treatment. Am J Psychiatry. 2008 Aug; 165(8):958-63. PMID: 18676600.
      View in: PubMed
    48. King B, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2006 Jan; 15(1):161-75. PMID: 16321729.
      View in: PubMed
    49. Bostic JQ, King B. Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug; 10(3):521-36. PMID: 16083327.
      View in: PubMed
    50. de Vries P, Humphrey A, McCartney D, Prather P, Bolton P, Hunt A. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry. 2005 Jul; 14(4):183-90. PMID: 15981129.
      View in: PubMed
    51. Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, King B, Pearson DA, Gernsbacher MA, Chez M. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004 Jan; 9(1):36-47. PMID: 14999174; PMCID: PMC4441220.
      View in: PubMed, PubMed Central
    52. Cromwell HC, King B. International Review of Research in Mental Retardation. The role of the basal ganglia in the expression of stereotyped, self-injurious behaviors in developmental disorders. 2004; 29:120-158.
    53. Hollander E, Phillips A, King B, Guthrie D, Aman MG, Law P, Owley T, Robinson R. Impact of recent findings on study design of future autism clinical trials. CNS Spectr. 2004 Jan; 9(1):49-56. PMID: 14999175.
      View in: PubMed
    54. Foster B, King B. Asperger syndrome: to be or not to be? Curr Opin Pediatr. 2003 Oct; 15(5):491-4. PMID: 14508298.
      View in: PubMed
    55. Dykens EM, Shah B, Sagun J, Beck T, King B. Maladaptive behaviour in children and adolescents with Down's syndrome. J Intellect Disabil Res. 2002 Sep; 46(Pt 6):484-92. PMID: 12354319.
      View in: PubMed
    56. Lewis MA, Lewis CE, Leake B, King B, Lindemann R. The quality of health care for adults with developmental disabilities. Public Health Rep. 2002 Mar-Apr; 117(2):174-84. PMID: 12357002; PMCID: PMC1497422.
      View in: PubMed, PubMed Central
    57. Stoddard FJ, Sheridan RL, Saxe GN, King BS, King B, Chedekel DS, Schnitzer JJ, Martyn JA. Treatment of pain in acutely burned children. J Burn Care Rehabil. 2002 Mar-Apr; 23(2):135-56. PMID: 11882804.
      View in: PubMed
    58. King B. Pharmacotherapy in mental retardation. Current Opinion in Psychiatry. 2002; 15:497-502.
    59. Mikhail AG, King B. Autism spectrum disorders: update of evaluation and treatment. Curr Psychiatry Rep. 2001 Oct; 3(5):361-5. PMID: 11559471.
      View in: PubMed
    60. King B, Wright DM, Snape M, Dourish CT. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 2001 Jun; 40(6):654-7. PMID: 11392342.
      View in: PubMed
    61. King B, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, Cantwell E, Davanzo PA, Dourish CT, Dykens EM, Hooper SR, Jaselskis CA, Leventhal BL, Levitt J, Lord C, Lubetsky MJ, Myers SM, Ozonoff S, Shah BG, Snape M, Shernoff EW, Williamson K, Cook EH. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001 Jun; 40(6):658-65. PMID: 11392343.
      View in: PubMed
    62. Mikhail AG, King B. Self-injurious behaviour in mental retardation. Current Opinion in Psychiatry. 2001; 14:457-461.
    63. Schroeder SR, Oster-Granite ML, Berkson G, Bodfish JW, Breese GR, Cataldo MF, Cook EH, Crnic LS, DeLeon I, Fisher W, Harris JC, Horner RH, Iwata B, Jinnah HA, King B, Lauder JM, Lewis MH, Newell K, Nyhan WL, Rojahn J, Sackett GP, Sandman C, Symons F, Tessel RE, Thompson T, Wong DF. Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev. 2001; 7(1):3-12. PMID: 11241877.
      View in: PubMed
    64. King B. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord. 2000 Oct; 30(5):439-45. PMID: 11098881.
      View in: PubMed
    65. Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard. 2000 May; 105(3):159-226. PMID: 10907489.
      View in: PubMed
    66. LaHoste GJ, Wigal T, King B, Schuck SEB, Crinella FM, Swanson JM. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. Exp Clin Psychopharmacol. 2000 Feb; 8(1):125-132. PMID: 10743913.
      View in: PubMed
    67. Madrid AL, State MW, King B. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child Adolesc Psychiatr Clin N Am. 2000 Jan; 9(1):225-43, x-xi. PMID: 10674198.
      View in: PubMed
    68. Szymanski L, King B. Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1999 Dec; 38(12):1606-10. PMID: 10596263.
      View in: PubMed
    69. Szymanski L, King B. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry. 1999 Dec; 38(12 Suppl):5S-31S. PMID: 10624083.
      View in: PubMed
    70. State MW, Dykens EM, Rosner B, Martin A, King B. Obsessive-compulsive symptoms in Prader-Willi and "Prader-Willi-Like" patients. J Am Acad Child Adolesc Psychiatry. 1999 Mar; 38(3):329-34. PMID: 10087695.
      View in: PubMed
    71. Cromwell HC, Levine MS, King B. Cortical damage enhances pemoline-induced self-injurious behavior in prepubertal rats. Pharmacol Biochem Behav. 1999 Feb; 62(2):223-7. PMID: 9972687.
      View in: PubMed
    72. Racusin R, Kovner-Kline K, King B. Selective serotonin re-uptake inhibitors in intellectual disability. Mental Retardation and Developmental Disabilities Research Reviews. 1999; 5:264-269.
    73. Dykens EM, Cassidy SB, King B. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. Am J Ment Retard. 1999 Jan; 104(1):67-77. PMID: 9972835.
      View in: PubMed
    74. Jacobsen J, King B, Leventhal BL, Christian SL, Ledbetter DH, Cook EH. Molecular screening for proximal 15q abnormalities in a mentally retarded population. J Med Genet. 1998 Jul; 35(7):534-8. PMID: 9678696; PMCID: PMC1051362.
      View in: PubMed, PubMed Central
    75. Philibert RA, King B, Winfield S, Cook EH, Lee YH, Stubblefield B, Damschroder-Williams P, Dea C, Palotie A, Tengstrom C, Martin BM, Ginns EI. Association of an X-chromosome dodecamer insertional variant allele with mental retardation. Mol Psychiatry. 1998 Jul; 3(4):303-9. PMID: 9702738.
      View in: PubMed
    76. Davanzo PA, Belin TR, Widawski MH, King B. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard. 1998 Mar; 102(5):427-37. PMID: 9544340.
      View in: PubMed
    77. Davanzo PA, Ke Y, King B, Guze BH, McCracken J, Curran J, Thomas A.Proton MR spectroscopy in four patients with Lesch-Nyhan Disease. American Journal of Neuroradiology. 1998; 19:672-674.
    78. King B, Lynn D.Self-injurious behaviour in mental retardation. Current Opinion in Psychiatry. 1998; 11:523-526.
    79. King B, Krishnamurthy J.Developmental aspects of stereotyped movement disorder. Psychiatric Annals. 1998; 28:313-316.
    80. King B, Cromwell HC, Lee HT, Behrstock SP, Schmanke T, Maidment NT. Dopaminergic and glutamatergic interactions in the expression of self-injurious behavior. Dev Neurosci. 1998; 20(2-3):180-7. PMID: 9691192.
      View in: PubMed
    81. Krishnamoorthy J, King B. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998; 8(2):107-13. PMID: 9730076.
      View in: PubMed
    82. King B, State MW, Shah B, Davanzo P, Dykens E. Mental retardation: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1997 Dec; 36(12):1656-63. PMID: 9401326.
      View in: PubMed
    83. State MW, King B, Dykens E. Mental retardation: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. 1997 Dec; 36(12):1664-71. PMID: 9401327.
      View in: PubMed
    84. Issues to consider in deaf and hard-of-hearing patients. The Committee on Disabilities of the Group for the Advancement of Psychiatry. Am Fam Physician. 1997 Nov 15; 56(8):2057-64, 2067-8. PMID: 9390099.
      View in: PubMed
    85. Dykens EM, Goff BJ, Hodapp RM, Davis L, Devanzo P, Moss F, Halliday J, Shah B, State M, King B. Eating themselves to death: have "personal rights" gone too far in treating people with Prader-Willi syndrome? Ment Retard. 1997 Aug; 35(4):312-4. PMID: 9270240.
      View in: PubMed
    86. Child and learning disability psychopharmacology. J Psychopharmacol. 1997; 11(4):291-4. PMID: 9443515.
      View in: PubMed
    87. Cromwell HC, King B, Levine MS. Pemoline alters dopamine modulation of synaptic responses of neostriatal neurons in vitro. Dev Neurosci. 1997; 19(6):497-504. PMID: 9445087.
      View in: PubMed
    88. Cromwell HC, Witte EA, Crawford CA, Ly HT, Maidment NT, King B. Pemoline produces ipsilateral turning behavior in unilateral 6-OHDA-lesioned rats. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Apr; 20(3):503-14. PMID: 8771605.
      View in: PubMed
    89. Davanzo PA, King B. Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. J Child Adolesc Psychopharmacol. 1996; 6(4):273-9. PMID: 9231320.
      View in: PubMed
    90. King B, Davanzo P.Buspirone treatment of aggression and self-injury in autistic and non autistic persons with severe mental retardation. Developmental Brain Dysfunction. 1996; 9:22-31.
    91. King B, Au D, Poland RE. Pretreatment with MK-801 inhibits pemoline-induced self-biting behavior in prepubertal rats. Dev Neurosci. 1995; 17(1):47-52. PMID: 7621748.
      View in: PubMed
    92. King B, DeAntonio C, McCracken JT, Forness SR, Ackerland V. Psychiatric consultation in severe and profound mental retardation. Am J Psychiatry. 1994 Dec; 151(12):1802-8. PMID: 7977889.
      View in: PubMed
    93. Forness SR, Kavale K, King B, Kasari C.Simple versus complex conduct disorders: Identification and phenomenology. Behavioral Disorders. 1994; 19:306-312.
    94. King B. Self-injury by people with mental retardation: a compulsive behavior hypothesis. Am J Ment Retard. 1993 Jul; 98(1):93-112. PMID: 8373567.
      View in: PubMed
    95. King B, Au D, Poland RE. Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats. J Child Adolesc Psychopharmacol. 1993; 3(2):71-9. PMID: 19630639.
      View in: PubMed
    96. Yuwiler A, Shih JC, Chen CH, Ritvo ER, Hanna G, Ellison GW, King B. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. J Autism Dev Disord. 1992 Mar; 22(1):33-45. PMID: 1375597.
      View in: PubMed
    97. King B, Poland RE. Comments on self-injurious behaviour. Am J Psychiatry. 1991 Nov; 148(11):1617-8. PMID: 1928505.
      View in: PubMed
    98. King B, McCracken JT, Poland RE. Deficiency in the opioid hypotheses of self-injurious behavior. Am J Ment Retard. 1991 May; 95(6):692-4; discussion 694-6. PMID: 1647799.
      View in: PubMed
    99. Brazell C, McClue SJ, Preston GC, King B, Stahl SM. 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125I]-iodoLSD binding at 5-HT2 receptors. Blood Coagul Fibrinolysis. 1991 Feb; 2(1):17-24. PMID: 1772986.
      View in: PubMed
    100. King B. Fluoxetine reduced self-injurious behavior in an adolescent with mental retardation. J Child Adolesc Psychopharmacol. 1991; 1(5):321-9. PMID: 19630681.
      View in: PubMed
    101. King B. Hypothesis: involvement of the serotonergic system in the clinical expression of monosymptomatic hypochondriasis. Pharmacopsychiatry. 1990 Mar; 23(2):85-9. PMID: 2187212.
      View in: PubMed
    102. King B, Liston EH. Proposals for the mechanism of action of convulsive therapy: a synthesis. Biol Psychiatry. 1990 Jan 01; 27(1):76-94. PMID: 1967536.
      View in: PubMed
    103. King B, Brazell C, Dourish CT, Middlemiss DN. MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype. Neurosci Lett. 1989 Oct 23; 105(1-2):174-6. PMID: 2562060.
      View in: PubMed
    104. Ford CV, King B, Hollender MH. Lies and liars: psychiatric aspects of prevarication. Am J Psychiatry. 1988 May; 145(5):554-62. PMID: 3282449.
      View in: PubMed
    105. King B, Ford CV. Pseudologia fantastica. Acta Psychiatr Scand. 1988 Jan; 77(1):1-6. PMID: 3279719.
      View in: PubMed
    106. King B, Baxter LR, Stuber M, Fish B. Therapeutic sleep deprivation for depression in children. J Am Acad Child Adolesc Psychiatry. 1987 Nov; 26(6):928-31. PMID: 3429415.
      View in: PubMed
    107. King B, Ford CV. Pseudologia fantastica. Am J Psychiatry. 1987 Jul; 144(7):970-1. PMID: 3605419.
      View in: PubMed
    108. King B, Bryant PJ. Developmental responses of the Drosophila melanogaster embryo to localized X irradiation. Radiat Res. 1982 Mar; 89(3):590-606. PMID: 6801720.
      View in: PubMed
    Bryan's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (393) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (12) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑